0001610717-23-000422.txt : 20231222
0001610717-23-000422.hdr.sgml : 20231222
20231222161432
ACCESSION NUMBER: 0001610717-23-000422
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231220
FILED AS OF DATE: 20231222
DATE AS OF CHANGE: 20231222
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: BELVIN MARCIA
CENTRAL INDEX KEY: 0001970752
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37587
FILM NUMBER: 231509936
MAIL ADDRESS:
STREET 1: C/O CYTOMX THERAPEUTICS, INC.
STREET 2: 151 OYSTER POINT BLVD., STE. 400
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CytomX Therapeutics, Inc.
CENTRAL INDEX KEY: 0001501989
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 273521219
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 151 OYSTER POINT BLVD.
STREET 2: SUITE 400
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650.515.3185
MAIL ADDRESS:
STREET 1: 151 OYSTER POINT BLVD.
STREET 2: SUITE 400
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
form4.xml
X0508
4
2023-12-20
0001501989
CytomX Therapeutics, Inc.
CTMX
0001970752
BELVIN MARCIA
C/O CYTOMX THERAPEUTICS, INC.
151 OYSTER POINT BLVD., STE. 400
SOUTH SAN FRANCISCO
CA
94080
true
SVP, Chief Scientific Officer
false
Common Stock
2023-12-20
4
S
0
4077
1.3805
D
155124
D
The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of PSUs previously reported on December 19, 2023.
Includes 116,875 restricted stock units.
/s/ Lloyd Rowland, as Attorney-in-Fact for Marcia Belvin
2023-12-22